Navigation Links
Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR

decision to advance KOS-1584 into Phase 2 trials in solid tumors. The Phase 2 program is anticipated to begin in the second half of 2007.

Data on KOS-1803 were presented in a poster titled, "KOS-1803: A New, Rationally Designed Epothilone Analog with an Improved Pharmacological Profile and Efficacy in Xenograft Mouse Models," at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, CA.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 (R1645) is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of th
'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... at 10 a.m. (Eastern Time) on Thursday, April 23, 2015, ... Investors and other interested parties may ... the Company,s website at www.jnj.com and clicking on ... the meeting will be made available a few hours after ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the reporting of data from ... Hydrochloride for Injection with the Delcath Hepatic Delivery ... presentation at the Society of Surgical Oncology (SSO) ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... ), the leading source of health information, ... on the new National Action Plan ... interview, President Obama emphasized the urgency and ... impact on national and global health.    ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Minocycline Showed Substantial,Reduction of Disease Activity in ... Treatment With Antibiotic Further Reduced Brain,Lesions and ... May 4, 2007 - New data from ... of Copaxone,(glatiramer acetate injection) along with the ...
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
Cached Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4
(Date:3/27/2015)... 2015 Ticket Down is a reputable source ... in Omaha, Nebraska on Friday, May 8th and Saturday, ... dates will be added in Omaha as Garth has done ... The Garth Brooks World Tour is continuing its run throughout ... Garth Brooks and Trisha Yearwood will bring their act to ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The report ... an essential source of information on and analysis of ... The population of the US in 2013 amounted to ... Rate (CAGR) of 0.8% from 2008. The country’s increasingly ... chronic diseases will help to boost the growth of ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... Irvine, CA (PRWEB) March 27, 2015 ... nation’s leading providers of business support services to dental ... opening of an affiliated Castle Dental office ... Lake Blvd. Hendersonville, TN 37075, this new Castle Dental ... they can receive the latest in comprehensive, quality dental ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3
... Gardner HealthDay Reporter , TUESDAY, May 3 (HealthDay ... to deployment or who,ve been injured during combat are more ... home. The PTSD tends to be worse with more ... of the Archives of General Psychiatry . The ...
... drug selectively kills the cancerous cells that cause chronic ... at the Ohio State University Comprehensive Cancer Center ... Research Institute (OSUCCC James). The study shows that ... lymphocytes that cause chronic lymphocytic leukemia (CLL). , ...
... or emergency medical technician providing first aid with a ... bleeding, fights bacteria (and other sources of infection), stimulates ... it is quickly absorbed by surrounding tissue may ... Or, imagine diabetics with hard-to-heal wounds finding a source ...
... develop a pioneering tool to help tailor the treatment of ... a new EU project. The 5-year AirPROM* project, which ... and physical models of the whole airways system, to help ... treatments. The news comes on World Asthma Day ...
... -- Few Americans bother to read the labels on over-the-counter ... drugs, ingredients, a new study says. This lack of ... a leading cause of acute liver failure in the United ... Acetaminophen, the active ingredient in Tylenol, is in more ...
... FOR DETERMINING SOURCE OF ACUTE SHORTNESS OF BREATH ... replace standard chest x-ray as the first choice of ... source of acute dyspnea is needed. Italian researchers studied ... strong agreement between the results of chest ultrasonography and ...
Cached Medicine News:Health News:Military Personnel With Mental Woes Before Deployment at Higher PTSD Risk 2Health News:Agent selectively targets malignant B cells in chronic leukemia, study shows 2Health News:New cotton candy-like glass fibers appear to speed healing in venous stasis wound trial 2Health News:New cotton candy-like glass fibers appear to speed healing in venous stasis wound trial 3Health News:New cotton candy-like glass fibers appear to speed healing in venous stasis wound trial 4Health News:Virtual lung models set to personalize asthma and COPD treatment 2Health News:Many Consumers Don't Know What's in Over-the-Counter Painkillers: Study 2Health News:Chest journal news briefs, May 2011 issue 2
... fits almost any arm -- simply bend the ... exact requirements. The cuffs are connected by an ... almost any elbow angle. The central part of ... contacts the elbow joint.,Special attention is paid to ...
... ankle splint may be used for either ... It is effective in stabilizing the ... after cast removal. The rigid pre-bent ... side-to-side support. The stays also help ...
... lightweight AFO is designed to assist ambulation ... neurological deficit resulting in drop-foot. The anatomically ... shoes. It is fabricated from specially formed ... term performance and reliability. For a more ...
... The VacoSplint has a rigid shell with a ... immobilized foot/ankle. The VacoSplint is a non-weight bearing ... bear he/she should transfer to the STORM walker ... the nylon liner from the STORM and insert ...
Medicine Products: